Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label, Dose-escalating, Phase I Trial With GEM3PSCA, a PSCA Targeted Bispecific Antibody Engaging T-cells, in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSCA Marker

Next Previous
Trial Profile

A Multicenter, Open-label, Dose-escalating, Phase I Trial With GEM3PSCA, a PSCA Targeted Bispecific Antibody Engaging T-cells, in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSCA Marker

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GEM 3 PSCA (Primary)
  • Indications Carcinoma; Non-small cell lung cancer; Prostate cancer; Renal cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions
  • Sponsors AvenCell Europe

Most Recent Events

  • 07 Jul 2023 Status changed from recruiting to discontinued as per business decision by sponsor.
  • 13 Jul 2022 The protocol was amended to exclude patients with breast and pancreatic cancer, according to ClinicalTrials.gov record.
  • 13 Jul 2022 Planned End Date changed from 1 Dec 2022 to 1 Jun 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top